May 15 (Reuters) - About 20 deaths linked to serious liver dysfunction have been reported in Japan in patients treated with Amgen's rare disease drug Tavneos, according to a safety notice issued by ...

The Japanese drugmaker that sells rare-disease medicine Tavneos said new patients will be able to get the drug, which carries risk of liver injury.

After the FDA flagged patient deaths linked to Amgen's rare disease drug Tavneos and called for its voluntary removal, the ...

Kissei Pharmaceutical, which sells the rare immune-disease drug in Japan, warned doctors to stop prescribing it to new patients.

A Japanese pharmaceutical firm has warned doctors against prescribing a drug for rare autoimmune diseases to new patients following the deaths of 20 people who took it. Kissei Pharmaceutical, which ...

Amgen is standing behind a rare disease drug that the FDA wants off the market due to safety concerns and alleged clinical trial manipulation, and its defense will include a new analysis of the ...

June 11 (Reuters) - Amgen said it has signed up a research firm to independently review data for its drug, Tavneos, as it ...

Kissei Pharmaceutical has revised a package insert in Japan for Amgen's rare immune-disease drug Tavneos, saying that serious liver dysfunction could occur. The Japanese pharmaceutical company said ...

Japanese drugmaker Kissei Pharmaceutical 45470.53%increase; up pointing triangle said doctors in Japan can again prescribe an Amgen AMGN 1.15%increase; up pointing triangle rare-disease drug to new ...